---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-002071"
form_type: "8-K"
ticker: "ELAN"
cik: "0001739104"
company_name: "Elanco Animal Health Inc"
filed_at: "2023-01-09T23:59:59+00:00"
generated_at: "2026-06-20T18:02:06.416246+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "medium"
source: SEC EDGAR
---

# Elanco discloses FDA submission for JAK inhibitor at JPM conference

## Summary
- Company notes Q4 2022 submission to FDA for its JAK inhibitor.
- Presentation made at 41st Annual J.P. Morgan Healthcare Conference on Jan 10, 2023.
- No financial results or guidance changes provided in the filing.

## SEC filing metadata
- accession: 0001104659-23-002071
- form_type: 8-K
- ticker: ELAN
- cik: 0001739104
- company_name: Elanco Animal Health Inc
- filed_at: 2023-01-09T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: medium
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1739104/000110465923002071/0001104659-23-002071-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1739104/000110465923002071/tm232554d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-002071
- JSON: https://secwatch.observer/filing/0001104659-23-002071.json
- Plain text: https://secwatch.observer/filing/0001104659-23-002071.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.